Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation in non-malignant disorders

G Kriván1, L Timár, V Goda

  • 1Bone Marrow Transplantation Unit, St. László Hospital, Budapest, Hungary.

Bone Marrow Transplantation
|January 23, 1999
PubMed
Summary

Hematopoietic stem cell transplantation offers a chance for survival in children with severe anemias and immune deficiencies. While overall survival is 67%, challenges like fungal infections and graft rejection impact outcomes, especially for certain genetic disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023
Same author

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Bone marrow transplantation·2019
Same author

Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.

Clinical radiology·2019
Same author

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Bone marrow transplantation·2019
Same author

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.

Blood cancer journal·2017
Same author

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Leukemia·2017

Area of Science:

  • Pediatric Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Hematopoietic stem cell transplantation (HSCT) is a critical treatment for various pediatric hematologic and immunologic disorders.
  • Understanding transplant outcomes in diverse patient populations is essential for refining therapeutic strategies.
  • This study evaluates HSCT outcomes in a cohort of children with severe anemias and primary immunodeficiencies.

Purpose of the Study:

  • To assess the overall disease-free survival and transplant-related mortality in pediatric patients undergoing HSCT.
  • To analyze the impact of specific diagnoses, donor types, and pre-transplant conditions on transplant success.
  • To identify factors contributing to graft rejection and non-engraftment in this cohort.

Main Methods:

Related Experiment Videos

  • A single-center retrospective analysis of 21 consecutive pediatric patients transplanted between January 1992 and December 1997.
  • Patients included severe aplastic anemia (SAA), severe combined immunodeficiency (SCID), Fanconi anemia, Diamond-Blackfan anemia, mucolipidosis, and mucopolysaccharidosis type I.
  • Transplant types included HLA-identical family donors, mismatched unrelated donors (MUD), and haploidentical family donors.

    • Main Results:

    • The 3.5-year overall disease-free survival was 67% (14/21), with a transplant-related mortality of 19% (4/21).
    • All SCID patients achieved disease-free survival; however, SAA patients with pre-transplant fungal infections had reduced survival (71% DFS).
    • Two patients with lysosomal storage disorders experienced graft rejection after haploidentical T-cell depleted transplants, and two cases of non-engraftment were successfully re-engrafted.

    Conclusions:

    • HSCT can achieve significant long-term disease-free survival in pediatric patients with severe hematologic and immunologic conditions.
    • Pre-existing fungal infections and specific genetic disorders like lysosomal storage diseases pose challenges to successful transplantation.
    • Further research into optimizing graft manipulation and supportive care is warranted to improve outcomes for high-risk pediatric transplant recipients.